Article Details
Retrieved on: 2024-01-15 19:41:27
Tags for this article:
Click the tags to see associated articles and topics
Summary
Ambrx Biopharma Inc., a biotech firm focused on antibody-drug conjugates for cancer treatment, experienced a turnaround from delisting to a $2 billion acquisition by Johnson & Johnson, highlighting the value of biopharma innovation.
Article found on: www.sdbj.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here